ENVERIC BIOSCIENCES, INC. Business Combination, Consideration Transferred
ENVERIC BIOSCIENCES, INC. (ENVB) reported Business Combination, Consideration Transferred of $2.61 million for the 12-month period ending 2016-12-31, per its 10-K/A filed 2017-04-04.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2017-04-04
- ENVERIC BIOSCIENCES, INC. business combination, consideration transferred for fiscal 2016 was $2.61M.
| Period end | Business Combination, Consideration Transferred 9 month | Business Combination, Consideration Transferred 12 month |
|---|---|---|
| 2016-12-31 | $2.61M 10-K/A · filed 2017-04-04 | |
| 2015-12-31 | $1.00M 10-K/A · filed 2017-04-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |